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Impaired axonal transport can contribute to axon
degeneration and has been described in many
neurodegenerative diseases. Multiple sclerosis (MS)
is a common neuroinflammatory disease, which is
characterized by progressive axon degeneration—
whether, when, and how axonal transport is affected
in this condition is unknown. Here we used in vivo
two-photon imaging to directly assay transport of
organelles and the stability of microtubule tracks in
individual spinal axons in mouse models of MS. We
found widespread transport deficits, which pre-
ceded structural alterations of axons, cargos, or
microtubules and could be reversed by acute anti-
inflammatory interventions or redox scavenging.
Our study shows that acute neuroinflammation in-
duces a pervasive state of reversible axonal dysfunc-
tion, which coincides with acute disease symptoms.
Moreover, perpetuated transport dysfunction, as we
found in a model of progressive MS, led to reduced
distal organelle supply and could thus contribute to
axonal dystrophy in advanced stages of the disease.
INTRODUCTION
Multiple sclerosis (MS) is an inflammatory disease of the CNS
and a frequent cause of neurological disability. In MS, chronic
disability is due to progressive axon degeneration (Trapp and
Nave, 2008). During the initial phase of the disease, axon degen-
erationpredominantlyoccurs in focalwhitematter lesions,while in
later stages of the disease, a more widespread pattern of axonal
pathology emerges (Lassmann et al., 2012). Such diffuse axonNedegeneration is reminiscent of the continuous decline observed
in classical neurodegenerative diseases, but the mechanisms
that causeprogressiveaxon loss inMSremainpoorly understood.
Axonal transport, which shuttles critical cell body-derived cargos
back and forth between soma, axon, and synapses (Coleman,
2005; Millecamps and Julien, 2013), appears to be a vulnerable
target in neuronal homeostasis. Indeed, impairments of axonal
transport have been associated with axon degeneration in neuro-
logical disease.First, transportdisturbanceshavebeendescribed
in several neurodegenerative conditions and appear to precede
the initiation of overt neurodegeneration (Millecamps and Julien,
2013). Second,mutations that cause neuronal and axonal degen-
eration in mice and humans often affect axonal transport (Baloh
et al., 2007; Ebbing et al., 2008) and, in converse, mutations that
affect transport can cause axon degeneration (Hurd and Saxton,
1996; LaMonte et al., 2002). Finally, therapeutic strategies that
restore transport tracks and reverse transport deficits have
been shown to slow the progression of axon degeneration, for
example, inmodels of Charcot-Marie-Tooth disease or hereditary
spastic paraplegia (d’Ydewalle et al., 2011; Denton et al., 2014).
While transport disturbances have thus been linked to clas-
sical neurodegenerative diseases, it is currently unclear whether
and when similar transport deficits occur in neuroinflammatory
lesions, how such deficits relate to structural axon damage,
and which inflammatory mediators can impede transport. Here
we use in vivo two-photon imaging to directly measure organelle
transport andmicrotubule dynamics in acute and chronic mouse
models of MS. Remarkably, we found that in neuroinflammatory
lesions axonal transport was not only reduced inmorphologically
altered axons, but also in the majority of normal-appearing
axons. Further analysis showed that transport impairments are
already present before demyelination or major abnormalities of
microtubule tracks became apparent. This indicates that trans-
port deficits represent an early and pervasive stage of axonal
dysfunction. Transport deficits recovered within days in an acute
MS model but failed to resolve in a chronic model, resulting in auron 84, 1183–1190, December 17, 2014 ª2014 Elsevier Inc. 1183
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Figure 1. In Vivo Imaging of Organelle Transport in Neuroinflamma-
tory Lesions
(A) In vivo two-photon image of the spinal cord of a control Thy1-YFP-16 3
Thy1-MitoCFP-P mouse (top) and a Thy1-YFP-16 3 Thy1-MitoCFP-P mouse
2 days after onset of EAE (bottom; axons, white; nuclei labeled by in vivo
application of Nuclear-ID Red, red; mitochondrial channel not shown). (B)
Magnified views of axons from neuroinflammatory lesions illustrating different
stages of axon morphology (N, axon from a control mouse; stage 0, normal-
appearing axon within an inflammatory lesion; stage 1, swollen axon within an
inflammatory lesion; corresponding symbols as shown on the right are used
throughout the figures). (C and D) In vivo two-photon time-lapse images of
control axons (top) and stage 0 axons imaged 2 days after onset of EAE
(bottom) with moving mitochondria (C), in Thy1-YFP-16 3 Thy1-MitoCFP-P
mice, and peroxisomes (D), in Thy1-OFP-3 3 Thy1-PeroxiYFP-376 mice,
represented as pseudo-colored overlays (lines represent tracks during the
indicated time period). (E and F) Quantification of anterograde (top) and
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1184 Neuron 84, 1183–1190, December 17, 2014 ª2014 Elsevier Inclasting impairment of distal organelle supply. Redox scavenging,
as well as acute anti-inflammatory interventions, quickly re-
stored transport levels, demonstrating that transport deficits
can be therapeutically ameliorated.
RESULTS
Widespread Deficits of Organelle Transport Are
Observed in Multiple Sclerosis Models
To investigate howorganelle transport is affected byneuroinflam-
mation, we used an acute experimental autoimmune encephalo-
myelitis (EAE) model of MS, in which inflammatory lesions with
axon damage evolve in the spinal cord of mice (Figures 1A and
1B). We then established a spinal in vivo two-photon imaging
approach (Davalos et al., 2008; Nikic et al., 2011) that allowed
us to follow the dynamics of individual fluorescently labeled
organelle cargos, such as mitochondria (in Thy1-MitoCFP mice;
Misgeld et al., 2007) or peroxisomes (in newly generated Thy1-
PeroxiYFPmice), in individual spinal axons in the healthy and in-
flamed spinal cord (Figures 1C and 1D and Movies S1 and S2
available online). Neuroinflammatory lesions were identified
in vivo by application of a nuclear dye that reveals cellular infiltra-
tion (Romanelli et al., 2013) or based on the local presence of
damaged axons (see Supplemental Experimental Procedures).
Our in vivo recordings showed that anterograde and retrograde
transport of mitochondria and peroxisomes were markedly
reduced in spinal axons that pass through these lesions (Figures
1E and 1F and Movie S1). Strikingly, transport was not only
reduced in axons that were swollen and hence had entered the
degeneration process (Nikic et al., 2011), but also in the majority
of normal-appearing axons in the lesion area. In contrast, dorsal
root axons imaged proximal to the lesion area displayed normal
anterograde transport and even increased retrograde transport
rates (FigureS1). In inflammatory lesions, such localized transport
deficits were not only observed acutely but persisted for several
weeks in a chronic EAEmodel (Figure S2A). These transport def-
icits resulted in a long-lasting reduction of net organelle delivery
from the soma toward the synapses, as anterograde transport
rates were more profoundly affected than retrograde ones. In
the case of mitochondria, for example, parts of axons that are
distal to inflamed sites lacked the supply of several hundredmito-
chondria per day (Figure S2B). Indeed, anterograde tracing of
dorsal root ganglion (DRG) axons that pass through the inflamed
spinal cord revealed that local axon collaterals within the lumbar
graymatter, aswell as thedistal axoncompartments in ascending
tractsof thedorsal thoracicspinal cord,becamedepletedofmito-
chondria in a chronic (but not in an acute) EAEmodel (Figure S3).retrograde (bottom) mean flux rate in control axons and EAE axons (imaged at
2 days after onset) for mitochondria (E) (n = 9–187 axons from 8–18 Thy1-YFP-
16 3 Thy1-MitoCFP-P mice per group; flux compared to control axons by
Kruskal-Wallis test followed by Dunn’s Multiple Comparison test) and perox-
isomes (F) (n = 153–157 axons from 6 Thy1-XFP 3 Thy1-PeroxiYFP mice per
group; flux compared to control axons by Mann-Whitney test). Pie charts
represent the percentage of axons at each stage where no transport was seen
(black slice, percentage indicated above). Scale bars represent 50 mm in (A),
10 mm in (B), and 5 mm in (C) and (D). All graphs show mean + SEM; **p < 0.01;
***p < 0.001.
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Figure 2. Mitochondrial Stop Duration In-
creases in EAE Axons
(A) Kymograph of a control axon (left) and a stage 0
axon, 2 days after onset of EAE (right) in Thy1-YFP-
16 3 Thy1-MitoCFP-P mice, serving to illustrate
the single mitochondrial transport characteristics
that we extracted from manually tracked organ-
elles, such as average speed, moving speed, and
stopping. (B) Quantification of single mitochondrial
transport characteristics (n = 81–454 mitochon-
dria, n = 43–100 stage 0 axons with normally
shaped mitochondria from 8–18 mice per group;
compared to control axons by Mann-Whitney
test). (C) Line diagram of mitochondrial stop du-
rations taken from 250 randomly chosen stops
organized from shortest (1) to longest (250). Inset
shows percentage of all tracked mitochondria
with persistent stops, not all displayed in line dia-
gram. Values in (B) expressed as mean + SEM.
***p < 0.001.
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Transport Deficits in MS ModelsTo better understand why organelle transport is impaired, we
tracked the movements of individual mitochondria through acute
neuroinflammatory lesions in normal-appearing axons. Our re-
sults show that while parameters such as moving speed and
stop frequency were only moderately altered, the duration of
mitochondrial stops was dramatically increased for both anterog-
radely and retrogradely moving mitochondria in neuroinflamma-
tory lesions. Furthermore, persistent arrests of organelles were
almost exclusively observed in the inflamed spinal cord (Figure 2).
Such persistent stops likely explain the increased density of or-
ganelles (mitochondrial density: 0.15 ± 0.003 mitochondria/mm2
in control axons compared to 0.25 ± 0.008 mitochondria/mm2
and 0.35 ± 0.02 mitochondria/mm2 in normal-appearing and
swollen axons within acute neuroinflammatory lesions, respec-
tively), as well as the raisedmitochondrial content (relative to con-
trol axons: 111%± 5%ofmitochondrial content in stage 0 axons,
128%±9%instage1axons), thatweobserved inneuroinflamma-
tory lesions in situ (n = 3–4 Thy1-YFP-163 Thy1-MitoCFP-SmiceNeuron 84, 1183–1190, Deand 10–35 axons per group). Indeed, such
organelle accumulations have also been
previously documented in MS tissue
(Vergo et al., 2011; Witte et al., 2009).
Transport Deficits Precede
Structural Alterations of Axons,
Cargos, or Microtubule Tracks
Wenext askedwhether focal structural al-
terations could explain why organelles
accumulate in neuroinflammatory lesions.
Demyelination or dysmyelination, for
instance, have been previously shown to
associate with increased organelle den-
sity in axons (Edgar et al., 2004; Kiryu-
Seo et al., 2010; Ohno et al., 2014). To
address the role of demyelination in vivo,
we labeled myelin in the intact spinal
cord using a vital dye (Romanelli et al.,
2013) and measured organelle transportin acute neuroinflammatory lesions. Interestingly, transport def-
icits were already present in myelinated axons (Figures S4A and
S4B) and were thus not secondary to demyelination.
Another possibility would be that damage to mitochondria
themselves, as described in neuroinflammatory lesions (Nikic
et al., 2011; Witte et al., 2014), might lead to transport disruption.
However, when we measured mitochondrial transport rates
in intact-appearing axons with either normally shaped or
morphologically altered mitochondria, we found that transport
deficits preceded structural changes to organelles (Figures
S4C and S4D).
Finally, we asked whether alterations of the microtubule
tracks, along which organelles travel, interfere with transport.
To assess the state of microtubules in individual axons at
different stages of neuroinflammatory damage, we analyzed
the orientation of microtubule tracks by electron microscopy
(Figures 3A–3C). In addition, we evaluated the presence of post-
translational modifications of tubulin, such as acetylation andcember 17, 2014 ª2014 Elsevier Inc. 1185
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Figure 3. Transport Deficits Occur before
Marked Alterations of Microtubule Tracks
(A–C) Ultrastructural analysis of axons in the lum-
bar spinal cord of a control mouse (A) and amouse
perfused 2 days after onset of EAE (B), stage
0 axon; (C), stage 1 axon. Top: overview trans-
mission electron micrographs of the axons;
bottom: larger magnifications (boxed on top)
illustratingmicrotubule morphology (arrows). Polar
plots, frequency histograms with angular orienta-
tion displayed in a circle, are on the right and
indicate the angle of deviation of microtubules
from the corresponding axon axis (percentages on
the left of the polar plot correspond to labels for the
concentric rings and indicate the proportion of
comets that are orientated in a given angle; n = 22–
65 axons from 3 mice per group). (D) In vivo
two-photon assay of dynamic microtubule ends
(‘‘comets’’) in control and EAE (2 days after onset)
Thy1-EB3-YFP mice. Top: in vivo time-lapse im-
ages of axons from control and EAE (2 days after
onset) Thy1-EB3-YFP mice (YFP, white). Comets
and their directionality are highlighted by arrows
(green, anterograde; pink, retrograde). Bottom:
polar plots that indicate the frequencies of the
angle of deviation of comets from the corre-
sponding axon axis, as well as their directionality.
Percentages of anterograde versus retrograde
comets are indicated above each polar plot.
Significantly fewer comets show an anterograde
orientation in stage 1 EAE axons (78% ± 5%)
compared to stage 0 EAE axons (94% ± 1%) and
control axons (96% ± 1%; p < 0.001 for stage 1
compared to stage 0 or control; Kruskal-Wallis test
followed by Dunn’s Multiple Comparison test). (E)
Quantification of comet density in control and EAE
axons (n = 12–49 axons per group from 4 control
and 6 EAEmice; densities in EAE axons compared
to control axons by Kruskal-Wallis test followed by
Dunn’s Multiple Comparison test). (F) Quantifica-
tion of both comet density and mitochondrial flux
per axon are plotted derived from recordings in
double-transgenic mice with differentially labeled
mitochondria and dynamic microtubule ends. Individual axons are indicated by circles with the mean of each group ±SEM indicated by a square. A clear shift to
the left within the EAE population indicates a decrease in organelle flux, while no change in comet density is apparent. Dotted gray line indicates 3 SDs from the
mean comet density in control mice showing that all stage 0 axons fall within the normal distribution and do not significantly differ from control (n = 33 axons per
group from 4 control and 3 EAEmice). Scale bars represent1 mm in (C), top (also for panels in A and B); 100 nm in blow-up in (C) (also for magnified details in A and
B); 5 mm in (D), right (also for middle and left). Graph in (E) shows mean + SEM; graph in (F) shows mean ± SEM for values indicated by square symbol; *p < 0.05.
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Transport Deficits in MS Modelstyrosination, which respectively indicate the stabilization or
destabilization of microtubules (Janke, 2014), by quantitative
immunohistochemistry (Figure S5). Finally, we directly assayed
the density and orientation of dynamic microtubules by in vivo
two-photon imaging of Thy1-EB3-YFP mice (Kleele et al.,
2014), which express a fluorescently tagged version of the
plus-end binding protein EB3 in neurons (Figures 3D–3F and
Movie S3). Together, these analyses showed that transport def-
icits occurred in axons before marked alterations of the microtu-
bule cytoskeleton. While there is a subset of normal appearing
EAE axons, which show increased microtubule tyrosination,
acetylation levels in EAE and control axons are similar, with
even a slight increase seen in normal-appearing axons in EAE
lesions compared to controls. Furthermore, the orientation of mi-
crotubules in electron micrographs, as well as the density and1186 Neuron 84, 1183–1190, December 17, 2014 ª2014 Elsevier Incorientation of dynamic microtubule comets, are comparable
between control and normal-appearing axons in EAE. In
contrast, we found disorganized, tyrosinated, and highly dy-
namic microtubules in a subset of swollen axons in neuroinflam-
matory lesions (Figures 3C–3E, Figure S5, andMovie S3). Such a
destabilization of themicrotubule cytoskeleton, which is reminis-
cent of microtubule changes induced after traumatic axon injury
(Erez et al., 2007; Kleele et al., 2014), might mark the transition
to more permanent structural axon damage and predispose
affected axons to subsequent degeneration.
Anti-Inflammatory and Anti-Oxidative Interventions
Reverse Transport Deficits in Multiple Sclerosis Models
Our results show that transport deficits can be initiated in mor-
phologically normal axons with intact myelin, normal-appearing.
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Figure 4. Transport Deficits Can Be Reversed by Glucocorticoid
Treatment and Redox Scavenging
(A) Schematic diagram (top) of the treatment of Thy1-YFP-163Thy1-MitoCFP-
Pmice with a single dose (20 mg/kg) of methylprednisolone 2 days after onset
of EAE followed by in vivo imaging the following day. Bottom: quantification of
anterograde and retrogrademitochondrial flux in EAEmice treatedwith vehicle
(‘‘Vehicle’’) or methylprednisolone (‘‘Treated’’) compared to untreated EAE
mice imaged at 5 days after onset (n = 33–79 stage 0 axons with normally
shaped mitochondria from 3–5 mice per group; flux in methylprednisolone-
treatedmice compared to flux in vehicle-treatedmice withMann-Whitney test;
‘‘nt,’’ not tested). Pie charts represent the percentage of axons where no
transportwas seen (black slice, percentage indicated above). As acomparison,
dashed gray line and gray pie chart represent average flux and percentage of
axons with no transport measured in healthy mice as shown in Figure 1. (B)
Schematic diagram (top) of bath application of the nitric oxide donor at a dose
that does not induce axonal degeneration (Spermine NONOate, 8 mM; ‘‘NO’’)
and theNO scavenger cPTIO (500 mM; ‘‘+cPTIO’’) to the exposed lumbar spinal
cord of control Thy1-YFP-163 Thy1-MitoCFP-Pmice. Donor was replenished
with fresh stock following each imaging timepoint to ensure continuous release
of NO. Bottom: quantification of anterograde and retrograde flux of mito-
chondria at different timepoints after NOdonor application (n = 22 axons from5
mice; flux compared to initial time point, ‘‘0,’’ by Kruskal-Wallis test followed by
Dunn’s Multiple Comparison test). Pie charts represent the percentage of
axons where no transport was seen (black slice, percentage indicated above).
(C) Schematic diagram (top) of the treatment ofThy1-YFP-163Thy1-MitoCFP-
P mice with i.p. injections of vehicle (‘‘Vehicle’’) or a ROS/RNS scavenger
cocktail (‘‘Treated’’) beginning at weight loss (‘‘1’’), and continued every 12 hr,
until 2 days after onset of EAE. Bottom: quantification of mitochondrial flux
measured at 2days after onsetwith accompanyingpie charts of thepercentage
of axons without transport (n = 156–158 stage 0 axons with normally shaped
mitochondria from 8 mice per group; flux compared to flux in vehicle-treated
mice with Mann-Whitney test). As a comparison, dashed gray line and gray pie
chart represent average flux and percentage of axons with no transport
measured in healthy mice as shown in Figure 1. All graphs show mean + SEM;
*p < 0.05; **p < 0.01; ***p < 0.001.
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Necargos, and unaltered microtubule tracks. Hence, transport def-
icits appear to represent an early state of inflammation-induced
axonal ‘‘dysfunction’’ rather than a later sequel of structural alter-
ations. This suggests that transport deficits could reverse once
the underlying inflammatory driving force subsides. Indeed,
transport deficits started to recover within a few days after the
peak of EAE in the acute model. This recovery could be acceler-
ated by treating mice at the peak of their symptoms with a single
dose of corticosteroids, an intervention that is commonly used to
curb disease exacerbation inMS patients (Sellebjerg et al., 2005;
Figure 4A). Next, we asked which inflammatory mediators could
cause such reversible axonal dysfunction. Reactive oxygen spe-
cies (ROS) and reactive nitrogen species (RNS) were previously
shown to induce transport deficits in vitro (Stagi et al., 2005) and
to initiate structural axon damage in vivo (Nikic et al., 2011). To
follow the evolution of transport deficits over time after applica-
tion of such reactive species, we repetitively measured axonal
transport in individual spinal axons of healthy Thy1-MitoCFP
mice for several hours. When we applied the NO donor, Sper-
mine NONOate, at a dose that did not induce axonal degenera-
tion, to the exposed spinal cord, organelle transport came to a
complete halt within 90min but could be restarted by application
of the NO scavenger cPTIO (Figure 4B and Movie S4). To deter-
mine whether reactive species also contribute to the induction
of transport deficits in neuroinflammatory lesions, we treated
EAE mice with ROS/RNS scavengers. Indeed, therapeuticuron 84, 1183–1190, December 17, 2014 ª2014 Elsevier Inc. 1187
Neuron
Transport Deficits in MS Modelsneutralization of reactive species not only limits structural axon
damage, as we have previously shown (Nikic et al., 2011), but
also ameliorated axonal transport deficits (Figure 4C).
DISCUSSION
By assaying the movement of individual axonal organelles in the
spinal cord of livingmice, we reveal widespread axonal transport
deficits in neuroinflammatory lesions. Transport deficits affected
diverse organelles such as mitochondria and peroxisomes and
both anterograde and retrograde transport.
A number of surprising findings emerged from of our study.
First, transport deficits were already observed in normal-ap-
pearing and myelinated axons, indicating that demyelination is
not required for initiation of inflammation-associated transport
deficits. At the same time, in line with previous studies (Kiryu-
Seo et al., 2010; Ohno et al., 2014), we find that demyelination
modulates important aspects of axonal transport including the
moving speed of anterograde organelle movement (0.31 ±
0.03 mm/s in normal appearing myelinated axons versus
0.49 ± 0.03 mm/s in all normal appearing axons in EAE, n =
17–81 mitochondria from 4–18 Thy1-YFP-16 3 Thy1-MitoCFP-
Pmice per group), as well as the density of stationary mitochon-
dria (93% ± 6% of control in normal appearing myelinated axons
versus 149% ± 5% of control in all normal appearing axons
in EAE, n = 30–128 axons from 4–18 Thy1-YFP-16 3 Thy1-
MitoCFP-P mice per group). It is thus likely that in neuroinflam-
matory lesions the final transport pattern reflects both the
influences of inflammation and demyelination, the relative
importance of which might shift as the disease advances. Sec-
ond, transport deficits occurred before marked alterations of the
ultrastructure or acetylation of microtubule tracks could be
observed. Imaging of fluorescently labeled microtubule end-
binding proteins further showed that the stability of microtubules
was likewise unaltered in the initial stage of axonal dysfunction
when transport deficits start to manifest. Third, transport deficits
were strikingly reversible, both spontaneously and after inter-
vention, suggesting that altered transport might be a suitable
therapeutic target. Indeed, both a standard anti-inflammatory
treatment, as well as a redox-scavenging protocol, efficiently
reversed the transport deficit.
So how does inflammation cause reversible transport deficits?
While multiple factors are likely to contribute, a number of obser-
vations point to alterations of motor engagement at the microtu-
bules. First, we did not find any structural changes of axons, car-
gos, or tracks that correlated with transport deficits, making it
unlikely that overt structural damage disrupts transport. Second,
both mitochondria and peroxisomes, as well as anterograde and
retrograde transport, are affected, making a primary interruption
of organelle-specific linkers, such as Miro or Trak (Schwarz,
2013), or of specific motors, such as kinesins or dynein, unlikely.
Finally, tracking of single organelles revealed that stop duration is
dramatically increased in the inflamed spinal cord, suggesting a
temporary disengagement of cargos from tracks. This notion is
further supported by the increased density and content of mito-
chondria observed in EAE axons that suggest that moving mito-
chondria accumulate in the lesion area. Indeed, arrest of moving
mitochondria (which are comparatively smaller than resting ones;1188 Neuron 84, 1183–1190, December 17, 2014 ª2014 Elsevier IncMisgeld et al., 2007 anddata not shown)might explain the drop in
the average mitochondrial volume observed in early stages of
axon damage, but which later normalizes as axon damage pro-
gresses, perhaps due to mitochondrial fusion or local growth
(relative mitochondrial volume: 63% ± 1% in normal appearing
axons and 97% ± 4% in swollen axons in EAE, n = 397–1,361
mitochondria from 3–4 Thy1-YFP-16 3 Thy1-MitoCFP-S mice
per group). The organelle accumulations we found could thus
be caused by local molecular alterations of microtubules that
affect binding of different motor-cargo complexes. Indeed, the
reduced severity and faster recovery of retrograde transport def-
icits we observed could be explained by the fact that dynein mo-
tors can circumvent such obstaclesmore efficiently than kinesins
(Dixit et al., 2008). While we observe a more prominent impair-
ment of the anterograde transport, it should be noted that in other
neurological conditions, e.g., in a mouse model of hereditary
spastic paraplegia, a selective accumulation of retrograde motor
proteins and consequent disturbance of retrograde transport
have been described (Edgar et al., 2004). Obstacles for organelle
transport could in principle result from posttranslational modifi-
cation and destabilization of microtubules, e.g., by tyrosination
or deacetylation (Dunn et al., 2008; Reed et al., 2006). Our results,
however, show no evidence for microtubule deacetylation and
indicate that microtubule tyrosination as well as changes in
microtubule dynamics primarily occur in the late stages of axon
damage (Figures 3C–3E and Figure S5). An alternative cause
for motor-to-track disruptions is the excessive attachment of
microtubule-associated proteins (MAPs), which can competi-
tively inhibit the binding of motors to microtubules (Dixit et al.,
2008). Notably, MAPs can be targeted by reactive oxygen or ni-
trogen species either directly (Stroissnigg et al., 2007) or through
activation of upstream kinases (Dias-Santagata et al., 2007). The
quick reversal of NO donor-induced transport deficits that
occurred after application of theNOscavenger cPTIO (Figure 4B)
is compatible with the idea that reversible MAP modifications
such as oxidation or phosphorylation mediate transport arrest.
Taken together, our data thus suggest that reactive species
released by activated immune cells in neuroinflammatory lesions
acutely induce transport disruptions by altering the attachment of
motor/cargo complexes to microtubules. Notably, these trans-
port deficits couldbe inducedbyNOdonor doses thatwere lower
than those that cause structural axon damage (Nikic et al., 2011).
This dose dependence of structural versus functional axon
impairments suggests that in an inflammatory lesion, there is a
center where high doses of reactive species induce structural
axon damage, surrounded by a larger ‘‘penumbra,’’ in which
lower doses of such mediators cause transient axonal dysfunc-
tion. Consequently, when inflammation subsides, for example
during remission of an acute neuroinflammatory lesion, transport
recovers within days in the penumbral zone. The localized nature
of the transport deficits we observe is underlined by our findings
that within dorsal root axons that reside outside the CNS and are
therefore not locally exposed to inflammation, anterograde flux is
normal, while retrograde flux is significantly increased compared
to control (Figure S1). The latter indicates that some cargoes
reverse when confronted with a structural or functional barrier,
similar to what occurs following traumatic axon transection (Mis-
geld et al., 2007).While transport deficits are thus locally induced,.
Neuron
Transport Deficits in MS Modelsthey likely also affect organelle flux in axons both proximal and
distal to the lesion area, which could further affect the transport
ratesmeasured in those axons that pass through several lesions.
Still, when short-lasting, such transport deficits probably have no
immediatedetrimental consequences for affectedaxons (Figures
S3C and S3D) and even structurally affected axons can recover
during remission (Nikic et al., 2011). However, in situations in
which inflammation persists, even at low levels, as in progressive
MS and its models, transport deficits are perpetuated. As anter-
ograde transport is predominantly affected, this limits the provi-
sion of vital organelles and ultimately results in ‘‘starvation’’ of
distal axonal arbors (Figure S3). Ensuing axonal dystrophy would
probably first manifest most distally at the synapse and follow a
‘‘dying-back’’ pattern (Coleman, 2005). Indeed, recent histopath-
ological studies provide evidence for prominent synaptic pathol-
ogy in progressive MS patients (Dutta et al., 2011; Mori et al.,
2013). Preventing persistent transport deficits, e.g., by prolonged
redox scavenging, might thus help to reverse transport-based
axon dysfunction and thereby help to counteract emerging
axonal dystrophy.
EXPERIMENTAL PROCEDURES
Transgenic Animals
In Thy1-YFP-16 (Jackson Laboratory strain designation: Tg(Thy1-YFP)
16Jrs/J), Thy1-OFP-3, and Thy1-CFP-5) mice, a large proportion of axons is
labeled, while the Thy1-GFP-S line labels only a small subset (Brill et al.,
2011; Feng et al., 2000). In Thy1-MitoCFP-P and Thy1-MitoCFP-S (Jackson
Laboratory strain designation: Tg(Thy1-CFP/COX8A)S2Lich/J) mice, a mito-
chondrial import sequence directs CFP expression selectively to neuronal
mitochondria (Misgeld et al., 2007). To study mitochondria transport rates in
the acute EAE model, we used double-transgenic Thy1-YFP-16 3 Thy1-
MitoCFP-P mice. To study mitochondrial transport in chronic EAE, we
obtained BiozziABH mice from Harlan Laboratories (strain designation
BiozziABH/RijHsd) and crossed themwith Thy1-MitoCFP-P or Thy1-MitoCFP-
S mice. F1 mice were used for analysis. Thy1-YFP-EB3-J045 mice, which
express a YFP-tagged version of the plus-end binding protein EB3 selectively
in neurons (Kleele et al., 2014) were used for in vivo microtubule ‘‘comet’’ anal-
ysis and crossed with Thy1-OFP-3mice to visualize axons or Thy1-MitoCFP-P
for concomitant imaging of mitochondria.
See details of the generation of peroxisome mice, in vivo microscopy and
analysis, tissue preparation and analysis, surgical procedures, and virus pro-
duction in Supplemental Experimental Procedures.
Statistical Analysis
All data sets were tested for normal distribution with the D’Agostino-Pearson
normality test using GraphPad Prism software. If the data sets failed said
test, a nonparametric test was chosen to compare the significance of means
between groups (Mann-Whitney test for two samples, Kruskal-Wallis test fol-
lowed by Dunn’s Multiple Comparison test for more than two samples). The
chosen statistical test is indicated in each accompanying figure legend along
with its corresponding p value if applicable.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and four movies and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2014.11.006.
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